Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients (AGINR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by University Hospital, Caen
Sponsor:
Information provided by (Responsible Party):
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT01930916
First received: November 16, 2012
Last updated: April 8, 2014
Last verified: April 2014
  Purpose

Oral anticoagulants vitamin K antagonists (VKA) have been used for many years in the treatment of thromboembolic disorders, which are among the most costly diseases in terms of public health resources. According to the Agence française de sécurité sanitaire des produits de santé (AFSSAPS), it was estimated at about 900,000 the number of patients treated with VKA in 2008 (more than 1% of the French population). VKA are at the origin of many adverse effects, given their narrow therapeutic window. They are the cause of the death of approximately 5000 patients per year. The use of this therapy is a priority axis of reflection for the Haute Autorité de Santé.

The interregion G4 (Nord Pas de Calais, Normandy, Picardy), with more than 9 million people, is particularly affected by this problem.

University hospitals of our interregion, given their very substantial regional referral activity, are actually involved in managing VKA adverse side effects.

Elderly population constitutes the majority of prescriptions. The main objective of this study is to compare INR of people older than 75 years measured by traditional method with those measured by capillary method with INRatio2 supply.

The secondary objective is to show that this measure is not affected by the presence or absence of anti-phospholipid antibodies, probably very prevalent in the elderly, as well as to test the variability of INR measurement between different hospital.


Condition Intervention
Blood Coagulation Disorders
Blood Coagulation Disorder With Prolonged Bleeding Time
Blood Coagulation Disorder With Prolonged Coagulation Time
Device: INR capillary measurement with INRatio 2 device
Other: antiphospholipid antibodies and lupus anticoagulant

Study Type: Interventional
Study Design: Endpoint Classification: Bio-equivalence Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Accuracy of a Portable International Normalized Ratio Monitor in a Population Aged 75 Years Old and Over

Resource links provided by NLM:


Further study details as provided by University Hospital, Caen:

Primary Outcome Measures:
  • INR by capillary method and INR by veinous punction [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]

    INR by the classical way (punction) and comparison with a capillary method tested here.

    INR by capillary method is done immediately after inclusion. INR by veinous punction is done on the 24 hours after the inclusion.



Secondary Outcome Measures:
  • Difference between International normalized ratio (INR) measured in a veinous blood punction and with a capillary method on the same patient and correlated to the level of phospholipid antibodies and lupus anti coagulant [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

    We want to know if the level of lupus and anti cardiolipin antibodies influence the value of INR measured by capillary method.

    lupus and anti cardiolipin antibodies tubes will be frozen after punction and analysed up to 1 year after.



Other Outcome Measures:
  • Difference of INR measurement by veinous method between Caen laboratory and the local center laboratory. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

    INR of a patient will be measured in two different center (Caen is the reference center).

    Blood sample will be frozen after punction and analysed up to 1 year after.



Estimated Enrollment: 150
Study Start Date: October 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Not interventionnal
INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
Device: INR capillary measurement with INRatio 2 device
INR capillary measurement with INRatio 2 device
Other: antiphospholipid antibodies and lupus anticoagulant
Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.

Detailed Description:

Adverse effects of oral anticoagulants (warfarin, fluindione mainly) are bleeding complications and concern 13% of hospitalizations, approximately 17,000 admissions per year. They constitute 12.3% of iatrogenic adverse effect according to the latest results of the survey conducted by the haute autorité de santé (HAS). A study realized in 2000, with 2976 patients, shows that 28.8% of patients were outside of any therapeutic range (<2 or> 4.5). In 2003, a third of french biologists had no knowledge of the indication of VKA treatment of patients at the INR measurement, and more than fifty percent in 2000. When the therapeutic range was known, the value of the INR remained outside it in 30% of cases. The median time between INR equilibration phase was 5 to 6 days, while the recommended time is 2 to 4 days. A quarter of patients in phase equilibrium treatment did not have a measure of INR at least once a month. Followed over a period of a year, patients spent 40% of the time with a value of INR outside the therapeutic range, high-risk area of ​​recurrent thrombosis or hemorrhage. That is why they require regular monitoring of INR.

Currently, this monitoring is done through a blood sample analyzed by a laboratory according to standard techniques.

The use of the INR measurement by capillary method provides a result in less than 3 minutes. This also allows the development of different monitoring strategies. In the context of a self-monitoring measure, the patient himself performs the test using the device and therapeutic adjustment is made by the health care professional.

Data analysis by HAS showed that the use of a self-measurement device significantly improved the time spent in the therapeutic range, reduced the risk of major bleeding and the accident major thromboembolism.

The pathologies treated by VKA are more common in the elderly. They are also more vulnerable to falls, overdoses of these treatments because their pharmacokinetics is amended by polypharmacy, malnutrition, less protein binding. The relative risk of bleeding is multiplicated by two beyond 70 years. Despite the emergence of new anticoagulants in the prevention of complications of arrhythmia (this disorder affect nearly 10% of the population aged over 80 years), VKA remains prevalent because these new drugs have renal elimination that can not be monitored, and can not be dialysable, have no antidote and represent a daily cost about 30 times the VKA.

The question of the use of devices for self-measurement of INR in the elderly is particularly timely, because this population has never had, to our knowledge, a specific evaluation of this technique.

Elderly population would derive the greatest benefit of this system because it will significantly improve the time spend in the therapeutic range, and reduce the risk of bleeding and thromboembolic events in reducing INR fluctuations.

We build a multicenter study whose main objective is to demonstrate the concordance of INR measurement by the capillary way (INRatio2 ®, SAS ALERE, Jouy-en-Josas) with venous technical reference. It concerns patients older than 75 years treated with VKA and hospitalized in Internal Medicine, Geriatrics and Vascular Medicine in the fours university hospital of the G4 region. The secondary objectives are to estimate the prevalence of antiphospholipid antibodies (ranging from 12 to 55% depending on the study) and their influence on the measurement of the INR by capillary method and the variability of the INR veinous measurement in function of the hospital, with a centralized INR measurement which allow to compare. 150 patients is required to perform this study.

  Eligibility

Ages Eligible for Study:   75 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient over 75 years
  • Recipient of the social security system
  • Patient receiving anti vitamin K treatment
  • Hospitalized in Internal Medicine, Geriatrics, Vascular Medicine
  • Having signed an informed consent to participate in the study

Exclusion Criteria:

  • Contraindication to a digital sampling.
  • Conditions preventing the realization of INRatio2 ® test : Amputation of the extremities, trophic disorders of the extremities.
  • Concomitant use of heparin.
  • Mental or physical illness which do not permit to consent to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01930916

Contacts
Contact: Boris Bienvenu, M.D, Ph.D +33 (0)2 31 06 45 84 bienvenu-b@chu-caen.fr

Locations
France
Centre hospitalier régional universitaire d'Amiens Not yet recruiting
Amiens, France, 80054
Contact: Marie-Antoinette Sevestre, M.D,Ph.D    + 33 3 22 45 59 30    sevestre.marie-antoinette@chu-amiens.fr   
Principal Investigator: Marie-antoinette Sevestre, M.D, Ph.D         
Sub-Investigator: Pierre Jouanny, M.D,Ph.D         
Sub-Investigator: Jean-Francois Claisse, M.D         
Centre hospitalier régional universitaire de Caen Recruiting
Caen, France, 14000
Contact: Boris Bienvenu, M.D,Ph.D    +33 (0)2 31 06 45 84    bienvenu-b@chu-caen.fr   
Principal Investigator: boris bienvenu, M.D,Ph.D         
Sub-Investigator: laurent Auboire, M.D         
Sub-Investigator: brigitte le mauff, M.D,Ph.D         
Sub-Investigator: Pablo Descatoire, M.D         
Centre hospitalier régional universitaire de Lille Not yet recruiting
Lille, France, 59000
Contact: Marc Lambert, M.D,Ph.D    +33 3 20 44 42 96    marc.lambert@chru-lille.fr   
Principal Investigator: marc lambert, M.D,Ph.D         
Sub-Investigator: Francois Puisieux, M.D,Ph.D         
Sub-Investigator: Eric Boulanger, M.D,Ph.D         
Centre hospitalier régional universitaire de Rouen Not yet recruiting
Rouen, France, 76000
Contact: Ygal Benhamou, M.D       ygal.benhamou@chu-rouen.fr   
Principal Investigator: Ygal Benhamou, M.D         
Sub-Investigator: Jeanne Yvonne BORG, M.D,Ph.D         
Sub-Investigator: Philippe Chassagne, M.D,Ph.D         
Sponsors and Collaborators
University Hospital, Caen
Investigators
Principal Investigator: Boris Bienvenu, M.D,Ph.D Centre hospitalier régional universitaire de Caen
Study Director: Jean Jacques Dutheil Centre hospitalier régional universitaire de Caen
Study Chair: Laurent Auboire, M.D Centre hospitalier régional universitaire de Caen
  More Information

Additional Information:
Publications:
Responsible Party: University Hospital, Caen
ClinicalTrials.gov Identifier: NCT01930916     History of Changes
Other Study ID Numbers: 2012-A00586-37
Study First Received: November 16, 2012
Last Updated: April 8, 2014
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Keywords provided by University Hospital, Caen:
Prothrombin Time/instrumentation
Prothrombin Time/utilization
Blood Coagulation Disorders/blood
Blood Coagulation Disorders/complications
Blood Coagulation Disorders/diagnosis
Prospective Studies
Adult
Reproducibility of Results
Point-of-Care Systems/utilization
Aged
Elderly

Additional relevant MeSH terms:
Disease
Blood Coagulation Disorders
Hemostatic Disorders
Pathologic Processes
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders
Antibodies
Antibodies, Antiphospholipid
Lupus Coagulation Inhibitor
Anticoagulants
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Hematologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 18, 2014